Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|March 22, 2022
Daily Medication Pearl: Asmanex HFA
Author(s)Saro Arakelians, PharmD
Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older
Advertisement
Medication Pearl of the Day: Asmanex HFA 100 mcg (mometasone furoate)
Indication:Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
Insight:
- Dosing: In patients 12 years of age and older, 2 inhalations twice daily of Asmanex HFA 100 mcg or 200 mcg.
- Dosage forms: Inhalation aerosol containing 100 mcg or 200 mcg of mometasone furoate per actuation.
- Adverse events: Most common adverse reactions reported in greater than or equal to 3% of patients included nasopharyngitis, headache, sinusitis, bronchitis, and influenza.
- Mechanism of action: Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity.
- Manufacturer: Merck
Sources:
Advertisement
Related to this article
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
3
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
4
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
5